ADOCIA SAS (ADOC.PA) Stock Price & Overview
EPA:ADOC • FR0011184241
Current stock price
The current stock price of ADOC.PA is 4.716 EUR. Today ADOC.PA is up by 4.71%. In the past month the price decreased by -24.3%. In the past year, price increased by 38.71%.
ADOC.PA Key Statistics
- Market Cap
- 92.481M
- P/E
- N/A
- Fwd P/E
- 25.22
- EPS (TTM)
- -0.56
- Dividend Yield
- N/A
ADOC.PA Stock Performance
ADOC.PA Stock Chart
ADOC.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ADOC.PA. When comparing the yearly performance of all stocks, ADOC.PA turns out to be only a medium performer in the overall market: it outperformed 52.47% of all stocks.
ADOC.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA. ADOC.PA may be in some trouble as it scores bad on both profitability and health.
ADOC.PA Earnings
On February 24, 2026 ADOC.PA reported an EPS of -0.5 and a revenue of 1.03M. The company missed EPS expectations (-2.12% surprise) and missed revenue expectations (-2% surprise).
ADOC.PA Forecast & Estimates
9 analysts have analysed ADOC.PA and the average price target is 15.5 EUR. This implies a price increase of 228.75% is expected in the next year compared to the current price of 4.716.
For the next year, analysts expect an EPS growth of -84.23% and a revenue growth -66.58% for ADOC.PA
ADOC.PA Groups
Sector & Classification
ADOC.PA Financial Highlights
Over the last trailing twelve months ADOC.PA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 63.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.67% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADOC.PA Ownership
ADOC.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 29.43 | 42.202B | ||
| 1AE | ARGENX SE | 29.42 | 42.19B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.117B | ||
| ABVX | ABIVAX SA | N/A | 8.555B | ||
| 2X1 | ABIVAX SA | N/A | 8.555B | ||
| GLPG | GALAPAGOS NV | N/A | 1.608B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.238B | ||
| PHARM | PHARMING GROUP NV | 48.82 | 1.036B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 975.338M | ||
| PHGN | PHARMING GROUP NV | 45.96 | 975.297M | ||
| IVA | INVENTIVA SA | N/A | 939.888M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ADOC.PA
Company Profile
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Company Info
IPO: 2012-02-20
ADOCIA SAS
115 avenue Lacassagne
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 77
Phone: 33472610610
ADOCIA SAS / ADOC.PA FAQ
What does ADOC do?
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
What is the current price of ADOC stock?
The current stock price of ADOC.PA is 4.716 EUR. The price increased by 4.71% in the last trading session.
Does ADOC stock pay dividends?
ADOC.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADOC stock?
ADOC.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ADOCIA SAS (ADOC.PA) stock traded?
ADOC.PA stock is listed on the Euronext Paris exchange.
Can you provide the growth outlook for ADOCIA SAS?
The Revenue of ADOCIA SAS (ADOC.PA) is expected to decline by -66.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.